Cencora INC. (Formerly Amerisourcebergen Corporation)
Pharmaceutical Distributor
Based in DC
🤖
AI Overview
With $1.8M in lobbying spend across 31 quarterly filings, Cencora INC. (Formerly Amerisourcebergen Corporation) is a significant lobbying presence.
$1.8M
Total Lobbying Spend
31
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $160K |
| 2019 | $240K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $180K |
| 2023 | $300K |
| 2024 | $240K |
| 2025 | $240K |
Lobbying Firms
KOUNTOUPES DENHAM CARR & REID, LLC
What They Lobby For
- Issues related to the pharmeceutical supply chain.
- Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances.
- Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including H. R. 3204, the Drug Quality and Security Act.
- Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of H. R. 3204, the Drug Quality and Security Act.
- Issues related to the distribution and pricing of medicines for pets.
- Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B.
- Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act.
- Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act. Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including those related to the drug supply chain.
- Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions.
- Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. Issues related to H.R. 6800, the Heroes Act. Issues related to drug shortage proposals.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.